ArticleTranslational lung cancer research2026

Neoadjuvant befotertinib plus vorolanib in resectable stage II-IIIB EGFR-mutant NSCLC: a study protocol for the prospective, single-arm phase I/II trial.

Leilei Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.